Duration of antidepressant use during pregnancy and risk of major congenital malformations

British Journal of Psychiatry

Volumn 192, Issue 5, 2008, Pages 344-350

  Ramos, Élodie ^a   St André, Martin ^a   Rey, Évelyne ^a   Oraichi, Driss ^a   Bérard, Anick ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; CONGENITAL MALFORMATION; DELIVERY; DEPRESSION; DYSTHYMIA; EYE MALFORMATION; FACE DEFORMITY; FEMALE; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; JAW MALFORMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PSYCHIATRIC DIAGNOSIS; PULMONARY VALVE DISEASE; RISK; SKULL MALFORMATION; TREATMENT DURATION;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES AS TOPIC; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 43749114055     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.107.042523     Document Type: Article

References (39)

1. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28: 137-52.
2. Deering S. Eating disorders: recognition, evaluation, and implications for obstetrician/gynecologists (1). Prim Care Update Ob Gyns 2001; 8: 31-5.
3. Lancet. Better news on population. Lancet 1992; 339: 1600.
4. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107-11.
5. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN, Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499-507.
6. Public Health Agency of Canada. Canada Prenatal Nutrition Program (CPNP). PHAC, 2002 (http://www.phac-aspc.gc.ca/dca-dea/programs-mes/ cpnp_participants_e.html).
7. US Food and Drug Administration Center for Drug Evaluation and Research. FDA Public Health Advisory Paroxetine 2005. FDA, 2005 (http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm).
8. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 18-27.
9. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87.
10. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 221-2.
11. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-10.
12. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Horn M, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8.
13. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713-8.
14. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14: 823-7.
15. Kinney DK, Yurgelun-Todd DA, Levy DL, Medoff D, Lajonchere CM, Radford-Paregol M. Obstetrical complications in patients with bipolar disorder and their siblings. Psychiatry Res 1993; 48: 47-56.
16. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45: 1093-9.
17. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165-71.
18. Franko DL, Blais MA, Becker AE, Delinsky SS, Greenwood DN, Flores AT, Ekeblad ER, Eddy KT, Herzog DB. Pregnancy complications and neonatal outcomes in women with eating disorders. Am J Psychiatry 2001; 158: 1461-6.
19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-9). WHO, 1978.
20. Régie de l'Assurance Maladie du Québec. Annual Statistics. Government of Quebec, 1997.
21. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007; 114: 1055-64.
22. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64: 496-509.
23. Martel MJ, Rey E, Beauchesne MF, Perreault S, Lefebvre G, Forget A, Blais L. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005; 330: 230.
24. Blais L, Beauchesne MF, Rey E, Malo JL, Forget A. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62: 320-8.
25. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
26. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995; 142: 428-36
27. New York State Department of Health. Congenital Malformations Registry - 1996 Report. Department of Health, 1996 (http://www.health.state.ny.us/ nysdoh/cmr/1996/append2.htm).
28. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-5.
29. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health 2005; 8: 214-20.
30. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-83.
31. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-92.
32. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982; 116: 114-22.
33. Tilley BC, Barnes AB, Bergstralh E, Labarthe D, Noller KL, Colton T, Adam E. A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol 1985; 121: 269-81.
34. Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S. comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 1991; 13: 91-6.
35. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 1103-12.
36. De Jong van den Berg LT, Feenstra N, sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology 1999; 60: 33-6.
37. Banhidy F, Lowry RB, Czeizel AE. Risk and benefit of drug use during pregnancy. Int J Med Sci 2005; 2: 100-6.
38. International Clearinghouse for Birth Defects Monitoring Systems. Annual Report. ICBDMS, 2003.
39. Murphy JM, Olivier DC, Monson RR, Sobol AM, Federman EB, Leighton AH. Depression and anxiety in relation to social status. A prospective epidemiologic study. Arch Gen Psychiatry 1991; 48: 223-9.